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Introduction: Anaplastic lymphoma kinase (ALK) fusion is the 
most common mechanism for overexpression and activation in non–
small-cell lung carcinoma. Several fusion partners of ALK have been 
reported, including echinoderm microtubule-associated protein-like 
4, TRK-fused gene, kinesin family member 5B, kinesin light chain 1 
(KLC1), protein tyrosine phosphatase and nonreceptor type 3, and 
huntingtin interacting protein 1 (HIP1).
Methods and Results: A 60-year-old Korean man had a lung mass 
which was a poorly differentiated adenocarcinoma with ALK overex-
pression. By using an Anchored Multiplex polymerase chain reaction 
assay and sequencing, we found that tumor had a novel translocated 
promoter region (TPR)-ALK fusion. The fusion transcript was gener-
ated from an intact, in-frame fusion of TPR exon 15 and ALK exon 20 
(t(1;2)(q31.1;p23)). The TPR-ALK fusion encodes a predicted pro-
tein of 1192 amino acids with a coiled-coil domain encoded by the 
5’-2nd of the TPR and juxtamembrane and kinase domains encoded 
by the 3’-end of the ALK.
Conclusions: The novel fusion gene and its protein TRP-ALK, harbor-
ing coiled-coil and kinase domains, could possess transforming poten-
tial and responses to treatment with ALK inhibitors. This case is the 
first report of TPR-ALK fusion transcript in clinical tumor samples and 
could provide a novel diagnostic and therapeutic candidate target for 
patients with cancer, including non–small-cell lung carcinoma.
Key Words: Lung cancer, ALK, TPR, Translocation.
(J Thorac Oncol. 2014;9: 563–566)
CASE DESCRIPTION
A 60-year-old Korean man was referred to a hospital 
because of a cough that persisted for 3 months. The patient 
had a history of tuberculosis 20 years ago. He was an ex-
smoker with a 30-pack-year history of regular smoking. On 
computed tomography scan of the chest, a 51-mm irregular 
mass and stable tuberculosis lesions were seen in the right 
upper lobe (Fig. 1A). The patient underwent lobectomy, which 
removed a lobulating grayish and yellow-tan solid tumor 
(Fig. 1B) that invaded the parietal pleural of the chest wall. 
Microscopic examination revealed that the tumor was a poorly 
differentiated adenocarcinoma with solid type (Fig. 1C). No 
mucinous components or signet-ring cells, which are usual 
features of ALK-positive adenocarcinoma, were identified. 
The tumor showed lymphatic invasion and metastasis into a 
single regional lymph node. The tumor did not have mutations 
in either epidermal growth factor receptor (EGFR) or Kirsten 
rat sarcoma viral oncogene homolog (KRAS). ALK antibody 
staining (dilution 1:50; clone 5A4; Novocastra, Newcastle, 
United Kingdom) was diffusively cytoplasmic and slightly 
granular (Fig. 1D). Break-apart fluorescence in situ hybridiza-
tion (FISH) analysis for ALK (Abbott Molecular, Abbott Park, 
IL) showed split 5’- and 3’-probe signals with occasional mul-
tiple signals (Fig. 1E and F).
During screening for ALK fusions in 533 lung adeno-
carcinoma tumors using an assay that we developed,1 we 
discovered that the tumor in this case had elevated ALK 3’ 
expression but low scores for known ALK fusion variants. 
These results indicated that the tumor might harbor a novel 
ALK fusion. Using an Anchored Multiplex polymerase chain 
reaction (PCR) assay for low amounts of low-quality forma-
lin-fixed samples (Dr. Zheng, personal communication) and 
sequencing (Ion Personal Genome Machine [PGM]; Life 
Technologies, Carlsbad, CA), we determined that tumor had 
a novel TPR-ALK fusion. Reverse-transcriptase PCR fol-
lowed by Sanger sequencing confirmed that the fusion tran-
script was generated from an intact, in-frame fusion of TPR 
exon 15 and ALK exon 20 (Fig. 2A). To assess this fusion 
event at the genomic level, we performed genomic PCR. 
The results indicated that the chromosomal translocation 
t(1;2)(q31.1;p23) had occurred by recombination between 
nucleotide 186,325,172 (nucleotide 246 downstream of the 
TPR exon 15) on chromosome 1 and nucleotide 29,446,944 
(nucleotide 550 upstream of the ALK exon 20) on chromo-
some 2. This translocation resulted in a novel TPR-ALK 
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fusion gene. The genomic sequence and cDNA sequence har-
boring and surrounding the translocation fusion points and 
the TPR-ALK fusion transcript were deposited in the National 
Center for Biotechnology Information databank. The TPR-
ALK fusion encodes a predicted protein of 1192 amino acids 
with a coiled-coil domain encoded by the 5’-end of the TPR 
and JM and kinase domains encoded by the 3’-end of the 
ALK (Fig. 2B).
The patient was treated with first-line adjuvant chemo-
therapy using vinorelbine and cisplain for four cycles. After 
18 months of follow-up, no evidence of recurrent tumor or 
distant metastasis was noted.
DISCUSSION
Lung cancer is a leading cause of global cancer mortal-
ity. In addition to the two oncogenes EGFR and KRAS, ALK 
is emerging as a molecular screening target for therapeutic 
strategies for pulmonary adenocarcinoma. The most com-
mon mechanism of ALK expression in tumors results from 
fusion of the ALK gene with another gene through chromo-
somal translocation.2 To date, five genes have been reported 
as fusion partners for ALK in lung adenocarcinomas: echino-
derm microtubule-associated protein-like 4 (EML4), TRK-
fused gene, kinesin family member 5B (KIF5B), kinesin light 
chain 1 (KLC1), and protein tyrosine phosphatase and nonre-
ceptor type 3. Recently, we reported that HIP1 was a fusion 
partner for ALK (in press).
TPR encodes a large coiled-coil protein that forms intra-
nuclear filaments attached to the inner surface of nuclear pore 
complexes (NPCs),3 which joins the inner and outer nuclear 
membranes and allows passive diffusion of ions and small 
molecules. The coiled-coil structure includes the first 1600 
amino acids of TPR and facilitates the assembly of homopol-
ymer or heteropolymer filaments.4 The TPR protein directly 
interacts with several NPC components. TPR is essential for 
the nuclear export of mRNAs and some proteins.5 Its position 
on the cytoplasmic side of NPCs suggests that it might extend 
fibrils from the nuclear pore into the cytoplasm.6 Oncogenic 
fusions of TPR with partner genes occur in some neoplasms. 
Gonzatti-Haces et al.7 first described a fusion of TPR with the 
met proto-oncogene (MET) oncogene. TPR-MET is created 
by a fusion between a 5’-region of TPR on chromosome 1 
and a 3’-region of MET on chromosome 7. Mutations in MET 
frequently deregulate the enzymatic activity of the tyrosine 
kinase receptor, activating its oncogenic potential. The fusion 
of TPR to MET facilitates autophosphorylation of the fusion 
protein, which shows oncogenic activity. The TPR-MET gene 
is overexpressed in gastric carcinoma and precursor lesions.8
FIGURE 1. A, Chest computed tomography 
with a 51-mm irregular mass in the right upper 
lobe (arrow). B, Cut surface of the lobectomy 
specimen showing a lobulating grayish and 
yellow-tan solid mass. C, Hematoxylin and eosin 
staining shows adenocarcinoma with a solid pat-
tern (×200). D, ALK immunohistochemical stain-
ing shows diffuse cytoplasmic pattern (×200). 
E and F, FISH assay of the ALK genomic rearrange-
ment with split 5’- and 3’-probe signals (red and 
green arrows) with occasionally increased ALK 
copy number.
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TRK-T1 is formed by an intrachromosomal rearrange-
ment that recombines the 5’-end of the TPR gene to a region 
encoding the tyrosine kinase domain of TRK.9 This fusion 
gene is found in papillary thyroid carcinoma and promotes 
neoplastic transformation of the thyroid epithelium.10 A TPR-
fibroblast growth factor receptor 1 (FGFR1) fusion was iden-
tified in myeloproliferative syndrome.11 TPR-FGFR1 might 
promote the malignant transformation of cells, as observed 
with other FGFR1 translocations. Different FGFR1 fusions 
are related to subtly distinct disease phenotypes. Clinical pre-
sentations of patients vary with fusion subtypes. For exam-
ple, patients with breakpoint cluster region (BCR)-FGFR1 
t(8;22) are clinically and hematologically similar to patients 
with t(9;22), which causes chronic myelogenous leukemia. 
However, patients with FGFR1 oncogene partner (FOP)-
FGFR1 t(6;8) or CEP110-FGFR1 t(8;9) show pathological 
phenotypes similar to chronic myelomonocytic leukemia.12
Among the known five fusion proteins that have ALK as 
a partner, KIF5B-ALK and KLC1-ALK show different stain-
ing patterns from the conventional EML4-ALK by anti-ALK 
immunohistochemistry. EML4-ALK tends to have a diffuse 
cytoplasmic staining pattern, but fusion proteins of ALK with 
KIF5B or KLC1 exhibit cytoplasmic granular staining with 
highlighted peripheral areas. This staining pattern suggests 
that the immunostaining phenotypes of tumor cells might be 
determined by the proteins that fuse with ALK. The novel 
fusion protein TPR-ALK presented in this case report showed 
a diffuse cytoplasmic staining pattern similar to the pattern of 
EML4-ALK.
We report a naturally occurring in vivo TPR-ALK fusion. 
A previous report showed that an artificial, in vitro–engineered 
TPR-ALK fusion protein could transform rat fibroblasts, and 
that retrovirus-mediated gene transfer of TPR-ALK into murine 
bone marrow developed immunoblastic B-cell lymphomas in 
the transplanted mice.13,14 A putative dimerization motif in the 
nucleophosmin portion of the fusion protein is essential for 
activating anaplastic large cell lymphoma cells and causing 
malignant transformation through phosphorylation of down-
stream molecules in tumor cells.15 Thus, the coiled-coil domain 
of TPR, which is similar to the dimerization motif in NPM, 
might contribute to the oncogenic potential of TPR-ALK. The 
previous results with artificially engineered ALK fusion pro-
teins strongly suggest that the novel naturally occurring in vivo 
TPR-ALK fusion generated by a translocation might have been 
oncogenic and caused the lung cancer and lymph node metas-
tasis observed in this case report.
Although the response of TPR-ALK to ALK inhibitors 
in lung cancers is unknown, ALK inhibitors might be an effi-
cient treatment for patients with TPR-ALK–positive cancer. 
The fusion TPR-ALK gene reported here and its fusion protein 
might be useful as biomarkers or therapeutic targets for future 
cancer diagnostics and treatment.
CONCLUSION
This case is the first report of TPR-ALK fusion tran-
script in non–small-cell lung carcinomas. Fusions of TPR 
with several partner genes occur and show oncogenic effects 
in some neoplasms. TPR protein contains coiled-coil domains 
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FIGURE 2. A, Schematic structure of the genomic 
DNA sequence (upper) and DNA sequence 
chromatograms (lower) showing fusion points 
for genomic rearrangement and TPR-ALK fusion 
transcript cDNA. B, Functional domain structures of 
TPR, ALK, and TPR-ALK proteins. TPR, translocated 
promoter region; ALK, anaplastic lymphoma kinase; 
JM, juxtamembrane.
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and the fusion protein possibly dimerizes constitutively, pos-
sessing transforming potential and responses to treatment 
with ALK inhibitors.
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